A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 17, 2025

Primary Completion Date

October 30, 2027

Study Completion Date

October 30, 2028

Conditions

Triple-Negative Breast Cancer (TNBC)

Interventions

DRUG

MR001 Bispecific Antibody for Injection

Intravenous infusion

Trial Locations (1)

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors

lead

Shenzhen Majory Biotechnology Co., Ltd.

INDUSTRY